Search

Displaying results 2211 - 2220 of 3020 in total
  1. Drug

    Imidafenacin

    go.drugbank.com/drugs/DB09262
    Investigational

    Imidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. It is marketed in Japan under the traden...

  2. Drug

    Nicotinamide adenine dinucleotide phosphate

    go.drugbank.com/drugs/DB03461
    Experimental

    (Dorland, 27th ed)

  3. Drug

    Mecasermin

    go.drugbank.com/drugs/DB01277
    ApprovedInvestigational

    Mecasermin contains recombinant-DNA-engineered human insulin-like growth factor-1 (rhIGF-1)[FDA Label]. … The rhIGF-1 protein is synthesized in bacteria (E. coli) that have been modified by the addition of the gene for human IGF-1.

  4. Drug

    Triheptanoin

    go.drugbank.com/drugs/DB11677
    ApprovedInvestigational

    [A214817] Triheptanoin was granted FDA approval on 30 June 2020.[L14612]

  5. Drug

    Peginesatide

    go.drugbank.com/drugs/DB08894
    ApprovedWithdrawn

    FDA approved March 27, 2012.

  6. Drug

    Sesame oil

    go.drugbank.com/drugs/DB11172
    ApprovedNutraceutical

    Sesame oil is considered an indirect additive used in food cotact substances by the FDA.

    Products: Pibubab Prestige Grain Ampule
  7. Drug

    Fitusiran

    go.drugbank.com/drugs/DB15002
    ApprovedInvestigational

    [L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B.

  8. Drug

    Dicyclomine

    go.drugbank.com/drugs/DB00804
    ApprovedInvestigational

    [L7982] Dicyclomine was granted FDA approval on 11 May 1950.[L7967]

  9. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve.

  10. Drug

    Insulin icodec

    go.drugbank.com/drugs/DB16693
    ApprovedInvestigational

    [L51078] In July 2024, the US FDA rejected the approval of insulin icodec, citing concerns regarding hypoglycemia and the indication being sought for type 1 diabetes mellitus. … [L51078]The US FDA subsequently approved insulin icodec in March 2026 for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [L56102]